Gender Identification
- Male/Female
Trisomies
- Trisomy 21 (Down Syndrome)
- Trisomy 18 (Edwards Syndrome)
- Trisomy 13 (Patau Syndrome)
Sex Chromosome Aneuploidies
- Turner Syndrome (Monosomy X)
- XXX (Triple-X)
- XXY (Klinefelter syndrome)
- XYY Karyotype
NIFTYTM is a highly accurate, Non-Invasive Prenatal Screening (NIPS) test for detecting genetic abnormalities including Trisomies and Sex Chromosome Aneuploidies.
NIFTYTM uses a blood sample from the pregnant mother to analyse the fetal DNA for chromosomal conditions, such as Down Syndrome (Trisomy 21) and Edwards Syndrome (Trisomy 18), from as early as 10 weeks of pregnancy. Gender determination is also available at no additional cost.
Cell-free DNA fragments (cfDNA) are short fragments of DNA which can be found circulating in the blood. During pregnancy, cfDNA fragments from both the mother and fetus are present in the maternal blood. The NIFTYTM test requires taking a blood sample from the mother, which is then analysed to detect chromosomal abnormalities in the fetus. Please note that a qualified person is required to collect the sample via a standard medical blood draw.
Our laboratory uses whole genome sequencing to analyse the fetal DNA. The entire genome is sequenced and compared against optimal reference chromosomes to accurately determine the presence of genetic abnormalities. Using this methodology, the NIFTYTM test is able to produce highly accurate results and screen for a broader range of abnormalities, including trisomy, sex chromosomal aneuploidy and deletion/duplication syndromes.
Many prenatal screening options already exist. However, compared to NIFTYTM, traditional screening methods have lower accuracy and higher false positive rates (as shown in the images below).
A false positive is where you receive a positive result for a test, when you should have received a negative result. NIFTYTM has a false positive rate of 0.05% only, which is much lower than other screening methods.
Invasive diagnostic tests, such as amniocentesis or chorionic villus sampling (CVS) are accurate but also carry a 1 – 2% risk of miscarriage. NIFTYTM is considered 100% safe for both the mother and unborn baby, as all that is required for testing is a 10ml maternal blood sample.
NIFTYTM is the most validated prenatal screening test on the market. NIFTYTM has a sensitivity greater than 99% from a study of nearly 147,000 pregnancies, and to date over 3 million tests have been carried out worldwide. You can read all the NIFTY® test’s published clinical data at www.niftytest.com/healthcare-providers/clinical-data/
For twin pregnancies Trisomy 21, Trisomy 18 and Trisomy 13 risk assessment results are available from the 12th week of gestation. Please note that some additional analysis may not be available. If you are carrying twins, and are interested in this test, please contact us for more information.
Results will be sent to your referring doctor within 15 working days, from receipt of your sample at our laboratory. Results may sometimes be delayed due to incorrect specimen handling or laboratory processes requiring repeat testing to ensure accurate results. If this is the case, we will endeavour to notify you as soon as possible.
Please note: Delayed results are not indicative of abnormal results.
Due to the nature of the test, a doctor’s referral is required. We recommend that you book an appointment with your doctor to discuss the testing and have our request form signed before proceeding with testing.
Your blood sample will need to be collected by a trained professional such as a doctor, nurse or phlebotomist. Please note, there may be a fee charged for collection. This fee is not included in the cost of testing and must be paid directly to your sample collector. If you are having trouble finding a sample collector, please contact us and we can help you find a collector in your area.
If you would like more information regarding this test, please contact us.
Please note that NIFTYTM is a screening test, and not a diagnostic test. A screening test indicates the risk of having a condition, and while they may be highly accurate, do not test with 100% accuracy. NIFTYTM is a screening test, so while it has a very high level of accuracy at 99.5% for detection of Down Syndrome (T21), Edwards Syndrome (T18) and Patau Syndrome (T13), it is not a diagnostic test and it does not screen for all chromosomal conditions. Please also note that this test cannot replace diagnostic tests such as Amniocentesis and Chorionic villus sampling, but it can help expectant mothers avoid the need to undergo these invasive tests. If the test result returns as high risk, further confirmatory diagnostic testing should be performed for final diagnosis by a qualified healthcare professional.
NIFTYTM is NOT suitable for patients with the following indications:
In some situations, a sample may produce no result. Reasons for NIL results:
No refund will be provided in the case of a NIL result.

Site Design, SEO, SEM and Management by Optimised